ArticleCancer management and research2025
Examining the Outcomes of Palliative Oophorectomy of Ovarian Metastases in de-Novo Metastatic Colorectal Cancer and Its Association with RAS Mutation Status: Insights from a Single-Institution Perspective.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Ovarian metastasis occurs in 3-5% of patients with CRC. Ovaries are considered sanctuary sites and typically do not respond effectively to chemotherapy. Patients with KRAS mutation generally have a worse prognosis compared to those with KRAS wild type. This study will discuss the effect of palliative oophorectomy on survival rates for those patients compared to chemotherapy alone. Methods: This is a retrospective study; we reviewed the charts of patients diagnosed with metastatic colorectal cancer at KHCC between January 2015 and December 2022. Out of 862 patients, 50 patients were eligible for the study; Patients were divided into two groups based on their treatment type, the palliative oophorectomy group and the chemotherapy alone group. The primary endpoint was a three-year median overall survival rate between the two groups. The secondary endpoints included three-year median progression-free survival and the difference in survival rate between the groups based on KRAS and BRAF mutation status. Results: In the oophorectomy group, the median overall survival (OS) was 19.3 months compared to 10.3 months in the chemotherapy alone group, with a P value of 0.05. Median progression-free survival (PFS) was also better in the oophorectomy group at 14.6 months compared to 9.4 months, with a P value of 0.59. For patients with KRAS mutation who underwent oophorectomy, the median OS was significantly better at 29.1 months compared to 10.3 months in the chemotherapy alone group, P value of 0.03. Conclusion: Our study indicates that palliative oophorectomy in metastatic CRC is associated with better survival. Even patients who harbor mutated KRAS, which typically have more aggressive disease behavior, showed better survival outcomes with oophorectomy compared to systemic chemotherapy alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.